Nufarm Limited (NUF) Earnings Call Transcript & Summary
May 23, 2024
Earnings Call Speaker Segments
Gregory Hunt
executiveThank you, Ashley, and good morning to all of you. It's a pleasure to welcome you to Nufarm's 2024 Interim Results Presentation, and we appreciate your time with us today. Before diving into the presentation, let me take a brief moment to point you toward the disclaimer on Slide 2, especially the statement concerning forward-looking statements. Turning to the result, even though the half brought challenging conditions, we remain pleased with how our strategies are progressing, strategies designed to create long-term value for our shareholders. Given the industry conditions we encountered, Nufarm produced a solid result for the first half of financial year '24. During the period, underlying EBITDA came in at $217 million and statutory NPAT was $49 million. An interim dividend of $0.04 per share was declared. Our focus stays on strategy, and we achieved important milestones in Crop Protection as well as across our seeds, omega-3 and carinata platforms. Now to the part I know you're all waiting for. For financial year '24, we anticipate EBITDA in the range of $350 million to $390 million. At the midpoint, that represents a 16% decrease from financial year '23 and a 17% decrease from the record EBITDA reported in financial year '22. As supply and demand dynamics continue to normalize, we anticipate a stronger second half than we saw in financial year '23. The midpoint suggests 25% year-on-year EBITDA growth in the second half of '24. While a decline in earnings never satisfies us, that would represent a very solid outcome given the conditions the industry has confronted. Our balance sheet remains in a strong position. Even with average working capital rising during the period, we stay highly focused and committed to driving efficient capital use across the business, and we expect average net working capital to come back within our target range, which Paul will address in detail later in this presentation. During the first half, we made substantial progress in reducing inventory. As of the 31st of March 2024, inventory stood 20% below the level at the 31st of March 2023; within Crop Protection, we cut inventory by $435 million year-on-year. We understand you'll have questions regarding the 3.6x leverage ratio for the half; we'd like to remind you that our debt financing offers considerable flexibility to accommodate working capital movements, our facilities carry minimal financial covenants, and all growth initiatives remain supportive. Assuming a normal seasonal unwind of working capital and phasing of profit, we expect to finish financial year '24 back at the upper end of our target range of 1.5x to 2x underlying EBITDA. We are on track to achieve our '26 financial aspirations, and we continue to see a healthy backdrop for the crop protection industry over the medium and longer term. Recovery from cyclically low prices is likely once channel stock issues are resolved, particularly in Brazil and parts of Europe. That should then produce a healthier alignment between supply and demand, along with prices reverting toward more historical norms. We keep growing our omega-3 and carinata plantings, and current planting intentions point to strong revenue growth in 2025; we are reaffirming guidance for '24 omega-3 revenue of $50 million to $70 million, plus our ambition to more than double omega-3 revenue in financial year '25. As planned, we are right now expanding and diversifying carinata plantings. Moving to segment results. Through the first half, the Crop Protection industry kept feeling the effects of growers and distributors cutting inventory back toward more normal levels. Those moves have hurt revenues and profit in this result. Lower grower and distributor inventory also affected manufacturer pricing. Appendix 11 of this presentation contains several charts showing how large the industry-wide price reductions have been. Our revenue and margins have taken a negative hit from these price reductions. These price levels, we believe, are temporary. And while the exact timing can't be predicted, we expect prices to come back to historical levels once the leftover effects of distributor and grower destocking have worked their way through the supply chain. Among recent data points, we have seen some tentative signs of prices rising for certain key herbicides. While the conditions I've mentioned hit our revenues and margins, we keep managing our business for the long term, with a focus on driving sustainable growth, improving the customer experience and delivering operational excellence. In the first half, we grew Crop Protection volumes. I point to this growth because it shows the strength of our market positions and the prospect of revenue and profit rebounding as supply and demand conditions return to more normal levels. In our seeds business, we achieved several important strategic milestones. We keep expanding base seeds in South America and see significant opportunity for further expansion in that region; we delivered omega-3 oil to customers in Chile, the U.S. and Canada and expanded our grower base for omega-3 canola to support further growth in financial year '25. Within certain Nutriterra segments in the U.S.A., we continue to progress discussions with potential partners for distribution and marketing. We reaffirm our guidance for FY '24, omega-3 revenue of $50 million to $70 million, and are on track to more than double revenue from the '24 financial year base in financial year '25. We keep expanding our geographical footprint for carinata planting. During the first half, we expanded planting in Argentina and the U.S.A., and we held launch events in France and Spain; in an important regulatory development, cover crops were included in Annex IXa of the European Union's Renewable Energy Directive. That inclusion ensures carinata holds a strong position as a feedstock for sustainable aviation fuel. This policy takes effect in June. Bringing cover crops into Annex IX sends a highly meaningful signal about what carinata will be worth, and how much of it will be needed, in EU sustainable aviation fuel markets going forward. Over the period, we hit additional milestones for energy cane, launching next-generation hybrids that deliver more biomass and sugar per hectare for the ethanol conversion that results; we also successfully widened our energy cane customer base in Brazil. And while revenue will take time to build, this represents one more endorsement of our bioenergy platform. Moving to regional results. In North America, our segment posted revenue of $637 million and underlying EBITDA of $48 million; we delivered strong volume growth in North America. Sales and margin were chiefly affected by weaker prices for nonselective herbicides. We raised revenue in Canada, with stronger volumes across several key brands fueling the volume increase. Our turf and ornamental business turned in a solid performance with revenue slightly lower year-on-year, and inventory fell year-on-year across the region. In APAC, revenues came in at $459 million and underlying EBITDA at $50 million. Favorable seasonal conditions along the East Coast of Australia and in Indonesia produced strong demand and brought inventory levels back to normal. Falling global prices for key products led to a year-on-year decline in net sales and margins, with historically low 2,4-D prices the main factor behind the reduced earnings.
Gregory Hunt
executiveAt Laverton, our 2,4-D plan is resuming operations following the upgrades and expansion of manufacturing capacity. The last phase of that upgrade is anticipated to occur in the latter half of the year. For our European segment, revenue reached $406 million, with EBITDA of $71 million. Sales and margins were adversely impacted by reduced volume and pricing stemming from poor weather conditions and distributor destocking. Additionally, lower sales volumes to industrial customers had a negative effect, driven by destocking within the agricultural segment and an extended slump in China's property market. Even though we advanced our reliability and asset integrity work at Wyke, those gains were outweighed by weaker volumes. Across every region, we continue to carry out strategies designed to deliver long-term profit growth and a better return on funds employed. We stay committed to running working capital more efficiently — this covers improved inventory, supplier and customer turns, tighter commercial disciplines and a more focused deployment of capital. Our reliability investments, which are meant to further enhance HSE performance and production capacity at the Wyke manufacturing facility, together with expanding capacity and lowering the cost of 2.4-D manufacturing at Laverton, should bring about stronger growth and profitability. Moving on to Seed Technologies, we achieved a solid performance there, generating $256 million in revenue alongside $76 million of EBITDA. The base seeds business was primarily fueled by year-over-year gains in Australia and South America. Results for sunflower in North America and sorghum in Brazil came in weaker as a result of reduced plantings. Seed treatment revenue also declined compared with the prior year, which reflected customer destocking. Over the half, we grew omega-3 product sales across the Americas, including Chile, the U.S.A. and Canada. Following approval of Aquaterra for use in Norway, we proceeded with commercial negotiations to enter that market; we also assisted in moving forward talks with prospective partners regarding distribution and marketing in certain U.S. nutraceutical segments. Turning to the expansion of our Nutriterra products: grower acceptance of omega-3 canola continues to rise. In the period, we broadened commercial contracts with growers to underpin anticipated sales growth in 2025. We finished the 2023 crop year with several audited and verified sustainability certifications for carinata, which can be used for sustainable aviation fuel, renewable diesel and sustainable maritime fuel. The 2023 Argentina crop harvest was successfully shipped to Europe and is now in the process of crushing sales alongside our partners. Nufarm and BP hosted a large launch event in March of this year to showcase the 2024 growing crop in Florida, with major airlines, mining companies, transport companies, policymakers and supply chain partners in attendance. Work is underway to grow supply for the 2024 carinata harvest, and we already hold expanded signed farm agreements in Argentina and Paraguay. Our inaugural season of contracting with growers, along with our geographic move beyond the Brazil market, is also far along, with farmer contracts secured. We have completed initial launch efforts in Spain and France ahead of small commercial-scale planting in 2024. Meanwhile, governments are increasingly adopting mandates and incentives designed to increase SAF output. The EU is progressing toward a 2% SAF mandate that begins in 2025. That requirement rises to 6% as of 2030 and hits 70% by 2050. Singapore recently unveiled a sustainable aviation fuel mandate too — starting at 1% of aviation fuel volumes in 2026, climbing to 3% to 5% come 2030. Proposals for SAF mandates have also been put forward by other nations, including Japan and the United Kingdom. As a final note on seed technologies, I'd flag that licensing revenue is part of the first half '24 result, and it wasn't booked during the first half of '23. That licensing revenue lands in the first half due to phasing, and a repeat in the second half isn't something we expect. Paul, over to you.
Paul Townsend
executiveGreg, thanks — and good morning, everyone. Reported revenue for the first half of fiscal '24 was $1.8 billion, and we posted underlying EBITDA of $217 million plus underlying NPAT of $51 million. Statutory NPAT came in at $49 million, so that underlying NPAT number was largely in line with it. We declared an interim dividend of $0.04 per share. Revenue was down 10% versus the prior year. Underlying EBITDA declined 31%, and underlying EBIT dropped 48%. Network capital leverage gets full treatment on slides later in the deck. One thing worth flagging: the year-ago comparison carries the expected swing in how EBITDA is phased across the two halves of financial year '24 relative to financial year '23. As you may remember, FY '23 EBITDA in the first half represented 72% of full-year EBITDA. For FY '24, the first half is expected to make up roughly 55% to 60% of full-year '24 EBITDA, as our guidance range indicates. This anticipated phasing change came about because the channel cut inventory and shifted toward replenishing stock in season, which pushed prices lower and, ultimately, squeezed margins. Crop protection revenue bridge. This slide presents the revenue bridge for our Crop Protection segment against the prior corresponding period. As expected, price had a negative effect on revenue during the period. Channel destocking drove market-wide cuts in active ingredient prices. Price cuts were passed along by formulators and distributors—our company among them—and that hurt revenue during the period. Turning to a brighter point, higher volumes contributed favorably to the revenue bridge for the half, with particularly robust growth in North America. We regard volume growth as significant because it serves our customers and positions us well for a future recovery in pricing. Currency fluctuations barely moved revenue. On operating cash flow, we recorded an outflow of $207 million for the half—far lower than the $559 million outflow in the first half of '23, reflecting net working capital at a more typical seasonal level. We posted a small decrease in net working capital compared with a year earlier. Throughout the quarter, we kept a strong focus on reducing inventory. That progress was partly offset by increased receivables and reduced payable balances as of period end, and we'll address this on the following slide. Consistent with earlier years, we anticipate a substantial cash inflow from net working capital movement during the second half. As an example, the three-year average receivables shift—or cash inflow—from the first half to the second half has amounted to $533 million. Net working capital. As of period end, net working capital was 3% lower than the prior year. We achieved substantial year-on-year inventory reduction, and the greater price from earlier periods in receivables showed that the second quarter ended stronger than it had a year before. The inventory result is one we view with particular satisfaction; we finished the period with inventory down 20% versus the equivalent period last year. Trade receivables were $133 million above the comparable prior period, which reflects a robust close to the first half. Payables stood $189 million below the comparable prior period, which reflects reduced ordering levels. Average net working to sales stood at 47%; that figure was above the prior corresponding period and chiefly mirrored the higher-than-normal inventory levels carried through this stretch of time because of the shift in customer ordering patterns and the seasonal build that typically happens in the first half. Looking ahead, via additional inventory reduction and normalization of payables, we anticipate getting back to our average net working capital to sales target of between 35% to 40% financial year '25. Inventory bridge; this shows our Inventory bridge. Inventory in our Crop Protection business dropped $435 million year-on-year and was driven by a lower volume of stock on hand. Inventory seeds rose to support the growth of that business. Taking everything into account, inventories were down 20% compared with a year earlier. On capital expenditure, CapEx totaled $110 million across the first half. Outlays on property, plant and equipment were in line with the same period a year ago, with the main drivers being our investments aimed at further gains in health, safety, environment, asset integrity and plant efficiency. As we noted when we reported full year '23 results, we intend to invest roughly $100 million each year for the next 3 years throughout the business on a variety of initiatives, Wyke in the U.K. in particular. Spending on intangibles and product development came to $54 million, and that figure contains some growth investment meant to back our revenue goals—specifically, creating new Crop Protection products, plus new hybrids and fresh market registrations for seeds. Within that growth investment was an initial $8 million outlay on a major project at Wyke, which we expect to total $140 million across the coming three years. Most of that money will be spent in financial year '25 and '26. As we've said before, this represents a very important, significant upgrade to our phenoxy capacity at the Wyke operation. And as we indicated in the financial year '23 full year results, total CapEx should land at roughly $240 million, in line with FY '23. I should add that we anticipate completing the divestiture of noncore property assets, which should bring in net proceeds of $40 million during the second half. Consistent with how we manage capital, we keep evaluating growth opportunities through the lens of return on funds employed, aiming for a return above Nufarm's weighted average cost of capital. Turning to net debt: we ended the period at $1.2 billion. Net leverage stood at 3.6x underlying LTM EBITDA. I want to reassure you that this ratio poses no problem for the company's debt facilities. Leverage exceeded the target range because of three things together: seasonal working capital, plus softer earnings during the first half, plus the second half of '23 contributing a smaller portion of full-year earnings than is typical for us. To show how that phasing worked, take second half '23 EBITDA and normalize it to a more normal 55 to 45 split between 1H and 2H for FY '23, and adjusted net leverage for the twelve months ended 31 March '24 would have been 2.9x underlying EBITDA. By the end of FY '24, we anticipate leverage will be at the higher portion of our 1.5x to 2x goal, provided that working capital unwinds as usual during the second half and we achieve our FY '24 EBITDA forecast. With Nufarm's debt facilities and available liquidity, we maintain a flexible and durable covenant-light capital structure that can handle fluctuations in net working capital; there are no refinancing needs in the near to medium term, and the group continues to have access to considerable cash and committed backed liquidity. FY '24 leverage expectations. I want to spend a few minutes covering the anticipated route back to 1.5x to 2x leverage in FY '24. This page's diagram is just a conceptual illustration, laying out the key pieces involved in this journey. As I noted before, the drop in net debt we expect across the second half should come primarily from receivables coming down seasonally.
Paul Townsend
executiveJust for reference, I noted that over the last 3 years, the average reduction in receivables in either the first or second half came to $533 million. We also expect a better balance between payables and inventory, since our stock replenishment work is bringing us back to a more normal cadence. Other cash items, such as CapEx, interest, cash taxes, dividends and so on, should broadly be covered by EBITDA. On the lower half of the chart, you can see the expected change in LTM underlying EBITDA under our guidance. Running a little math on those items should show you a credible path back to within, noting more toward the upper end of the 1.5x to 2x leverage at the close of FY '24. Importantly, the reduction in receivables we anticipate rests on a normal unwind of working capital there, specifically the seasonal phasing of sales and collections. If sales, say, were weighted more heavily toward the end of the second half, then the return to our leverage target would be delayed. Even in that case, we would still expect to get back within range only a few months after the close of FY '24. Also, moving back within the target leverage range assumes we hit our EBITDA outlook for FY '24. I hope this page helps inform your view of the anticipated path back to our leverage timing range. And last, on other expected financial items, this slide outlines our expectations for a number of them to help with your forecast. Corporate costs for full year '24 should be marginally below the prior corresponding period. Depreciation expense in the second half should be broadly in line with the first half. Second half net interest expense should be marginally above first half interest expense, and the tax rate should be 23% for full year '24. I'll now hand back to Greg.
Gregory Hunt
executiveThank you, Paul. I'd like to spend a bit of time on the pricing environment and what we expect for price recovery once the current destocking phase is behind us. On the left-hand side of this page, the chart demonstrates that prices for crop protection products right now sit well under the historical average, a result of the temporary effects of distributor destocking, which has pushed manufacturers to sell product at lower prices. That data comes from independent sources, Agbioinvestor and BAIINFO. Our belief is that the problems weighing on prices will be largely worked through over the course of calendar year 2024. There's extra stock sitting with distributors and around the world—especially in Brazil and Europe—and we think most of it gets worked off over the course of calendar 2024. As that distributor and grower supply comes down, we look for it to settle back to normal and create a healthier match between what's demanded and what's available. That, in turn, ought to return our manufacturing stockpiles and run rates to usual levels. Our read is that this lays the groundwork for pricing to come back toward its long-run averages in the near-to-medium term. We can't say precisely when the price turnaround arrives, but in general terms we see price acting as a favorable force for revenue and profitability past FY '24. On this slide, and for a number of the ones that follow, we'd like to walk you back through the journey our business is on and explain why we feel confident about hitting our revenue aspirations. As a reminder, in our Crop Protection business we're aiming for revenues of $3.8 billion to $3.9 billion by financial year '26. Reaching that goal depends on management forecast and presumes a return to normal long-term average prices. Market prices are the biggest factor we can't control. A great many of the other inputs required to get us to that aspiration sit within our control. From 2016 through 2021, we reset the cost base of our Crop Protection business. During that period, we shut down several plants and implemented a performance enhancement initiative across Europe. We acquired the Century and FMC portfolios in order to achieve the scale required for success in our European operations; we also inaugurated our cutting-edge formulation plant located in Greenville, Mississippi. In addition, we sold off our Crop Protection division in South America, in part since we felt we lacked the appropriate approach to thrive in that market at that point. Moving forward on the timeline. We have been completing the investment initiatives at our facilities, and Wyke is the final one among our major manufacturing sites that needs substantial investment in the near future. During our 2022 Strategy Day, we pointed to 22 significant portfolio initiatives that we felt would aid—or assist in aiding—the achievement of our FY '26 revenue targets. As of right now, I can report that the majority of those initiatives are either already launched or currently launching. Looking ahead to 2025 and 2026, we expect market prices to recover. Our aim is to continue strengthening our position in phenoxy herbicides while completing the rollout of the new products we are introducing. As a reminder, we ended with a market of $70 billion. That market is largely off patent, and that means there are only a few barriers standing in the way of us competing with innovative formulations that are affordable and effective for growers. Rising incomes in the population and demand for food provide a strong backdrop for demand. Moving to the following slide. On this page, we show how development of our omega-3 platform is progressing. By this point, all of you should be familiar with the foundation of our omega-3 strategy. Our omega-3 canola addresses a growing need for a sustainable substitute for fish oil so as to satisfy rising demand for omega-3 in aquaculture, food manufacturing and dietary supplements. We've come a long way in a short period, and at this point we're rapidly expanding our omega-3 operation. During the past several years, we've continued to grow both our farmer partnerships and our commercial revenue across Chile, the United States, and Canada. Approval to market Aquaterra in Norway came our way in 2023, and we anticipate commercial sales there during 2025. For Aquaterra, Norway represents a sizable and significant market. We've likewise mentioned that regulatory relaxation serves as a key lever on our production costs. It's a pleasure to report that our progress on this front remains steady. During the earlier part of 2024, we obtained permits related to Phase 2 in-country verification in China. That's a required step for satisfying the regulatory approval conditions in that nation. As we've mentioned before, partnerships might serve as a key avenue for expanding Nutriterra's footprint in the human supplements and food ingredients sectors. In the period, we named Connoils our exclusive collaborator for manufacturing and distributing Nutriterra DHA canola oil in powder form. Connoils ranks among the top global makers of oil powders, distributors, and wholesale providers of bulk oil ingredients; through 2025 and '26, we anticipate further scaling of omega-3 output. While aquafeed remains our primary focus, we likewise anticipate expansion opportunities, likely via partnerships in human nutrition and other market segments. Biofuels represent a growth platform for Nufarm over the long term, reaching far past what we aim to achieve by '26. Carinata was introduced by us in Argentina during 2018, and in 2022 came our initial shipment of carinata destined for commercial-scale crushing. A 10-year partnership with BP was set up by us to help scale Carinata production and sales; during 2023, we broadened production into the U.S.A. and brought out our first hybrids. Come 2024, we are extending production further across the Southern U.S.A. and Argentina, plantings have been launched by us in Brazil, and launch events were also held in France and Spain. Starting in 2025, SAF markets move into a significant phase as mandates take effect across a number of major aviation markets. Starting in 2025, the EU's SAF mandate takes effect with a 2% blending requirement at first; that figure rises to 6% by 2030 and then climbs sharply until it hits 70% in 2050. Singapore's mandated SAF program kicks off in 2026, and policies have been announced by both Japan and the U.K. that call for at least 10% mandated SAF blending by 2030. We also noted that cover crops now appear in Annex IX of the EU's Renewable Energy Directive. Energy cane remains at an earlier stage of development, but during the period we hit an important milestone by growing our customer count past 40 million. Our biofuels platform has a strong future ahead. Turning now to outlook. Despite some near-term headwinds, we believe the sector's long-term fundamentals are still solid. A larger population and higher incomes are driving bigger worldwide food requirements, and that fuels expansion in seed and crop protection offerings. Omega-3, carinata and energy cane bring additional diversified growth to Nufarm. Our fiscal 2024 guidance calls for underlying EBITDA in the range of $350 million to $390 million. At the midpoint, that guidance represents a 16% decline versus financial year '23 and 17% below the record underlying EBITDA we reported in financial year '22. We anticipate relatively strong growth during the second half of '24, and the midpoint of guidance implies 25% year-on-year EBITDA growth for that second half. To build on my earlier point, a drop in earnings is never something we're happy about. Even so, given what the industry has been through, 25% growth in the second half versus a year ago would represent a strong result. Our omega-3 guidance stands: revenue of $50 million to $70 million for fiscal '24, and omega-3 canola plantings in 2024 underpin our goal of more than doubling omega-3 product revenues in fiscal '25. We remain on track toward our targets of $3.8 million to $3.9 million in Crop Protection revenue and $600 million to $700 million in seed technologies revenue in financial year '26; this is based on management's forecast and presumes pricing returns to its long-term average proportion. Given what we covered today, we anticipate that pricing across the crop protection sector will return to normal. It's impossible to say exactly when that will happen, though recent figures offer encouraging evidence that prices are leveling off. As we've said before, our product pipeline is robust, and we look for substantial growth in omega-3 as well as in our base seeds business. Our biofuels platform—which includes carinata and energy cane—keeps growing and gives us a solid foundation for future earnings contribution. With that, I'll conclude and turn things back to Ashley for Q&A.
Evan Karatzas
analystPerhaps to begin with, could you give us a sense of what you anticipate across the different regions in the second half — how demand looks? Margins, and so on?
Gregory Hunt
executiveYes. Thanks, Evan. So at a broad macro level, I'd say — as I mentioned during the presentation — that market fundamentals are still fairly solid. Grain prices have come down from the record highs we saw, but they're still comparatively elevated; demand for grain, oilseeds and biofuels is therefore strong, and that ought to underpin seed sales. And I suppose grain prices where they sit today mean farmers will keep aiming to maximize yields. As a result, demand for crop protection products stays strong. If we look at — well, another point, too, is that distributors and farmers are buying nearer to the application window, which genuinely backs our view that we'll shift our half-on-half phasing in North America, with 70% of the U.S. corn and 60% of the soybean crops planted. Corn is at roughly 50%. So that's typical for this time of year. On seasonal conditions, most of the country is seeing average or better than average conditions. Canada has been somewhat slower, with rainfall and below normal temperatures having delayed plantings. So we'd describe the second-half prospects as positive. We expect in-crop applications and channel destocking to drive higher volumes and, as a result, a stronger second half than we saw in '23. Here in Australia, the Australian winter crop is the main driver. WA and South Australia remain fairly dry. Plantings are nonetheless underway, though, and we're assuming — assuming follow-up rainfall, we'd expect a bigger post-emergent application. As most of you know, conditions on the East Coast here are generally quite favorable. And going back to last year, demand was very weak in the second half of '23, since prices were falling and we saw significant margin contractions, particularly with regard to 2,4-D. That has now normalized; so in the second half of this year, we're expecting volume growth to deliver a stronger second-half result versus '23. In Europe, we've had very wet conditions in the U.K. and the northern parts of Europe, and that has delayed the season, pushing sales out of Q2 into Q3. Conditions in Southern Europe are generally positive, which contrasts with last year, if you recall, when the season was very, very dry. So that positions us for a stronger second half in the Southern parts. And one more thing I think I'd highlight is that we're seeing greater insect pressure. So that's driving demand for acetamiprid, which was one of the key products we acquired in the Century portfolio. Also, fresh market and label approvals have come through, and those should boost our contribution in the second half of this year; on the seeds side, however, conditions in Western Australia are very dry right now, which means canola plantings will be lower this year. And as I mentioned earlier, we remain pretty much on schedule for omega-3 and carinata planting. So overall, Evan, our view is that pricing will improve somewhat in the second half; that said, the biggest factor lifting the second half of '24 compared with '23 is going to be higher volume.
Evan Karatzas
analystYes. Perhaps just one more, if I may. I'm looking at Slide 9 right now — that $390 million impact from price. Obviously, there would have been some degree of COGS reduction, which offsets it by the time you reach gross profit. But I'm just trying to get a handle on, within that $390 million, how much gross profit impact came from selling through some of the out-of-money inventory? And should we still expect that to be a problem in the second half? Or has all of that out-of-money inventory now been fully sold through and washed out?
Paul Townsend
executiveYes. Look, there's no question Greg called it out. Margin pressure has been there. So while we've been able to make some margin, it's been fairly thin, since we hadn't actually been able to recover that through price. So that took place in the first half. Look, we do expect that to carry on to some degree. That said, as Greg mentioned, we're also expecting some good seeds, or some shoots if you like, of pricing recovery, but volume growth is what we expect in the second half to really deliver — we're not depending on pricing as such, but also to say there's an element of modest pricing. So margin ought to expand in that second half through a bit more upward pressure on pricing, plus having sold through some of the higher-priced inventory.
Gregory Hunt
executiveSo Evan, let me just add a bit more color to that. In North America, where we're a major player in nonselective herbicides, I'd say we've worked that inventory down, and the same holds in Australia. In Europe, because of the conditions in the second half of '23, we're still carrying some inventory there. But again, the bigger challenge in Europe centers more on insecticides and fungicides. We've diversified our portfolio, so we do carry some inventory in insecticides and fungicides. But largely in all the other regions, I'd say we've mostly worked through it — apart from Europe, we've worked that inventory through. Another thing I'll highlight or point out: we discussed Brazil in our prepared remarks. We don't operate in Crop Protection in Brazil, and as we understand it, there are still higher inventories of product in Brazil, and we believe that will work its way through over the balance of 2024. That matters because a lot of product made in China would go into that market, and it's now still trying to find its way into the Northern Hemisphere and the Australian market.
John Purtell
analystI have a few questions, if you don't mind. Greg, I appreciate the detail on that, specifically regarding some of the inventory. But I guess, taking a wider industry view, where would you say channel stock stands right now? By what it sounds like, is it still elevated in Europe while other regions are taking deliveries?
Gregory Hunt
executiveYes, John, I believe it comes down to the mix. As I mentioned, in North America we've mostly cleared things out. And I don't think it's only us — we're definitely confident that our inventory has been worked through in North America and in Australia. But speaking generally, the industry has done the same. The difficulties are genuinely in Brazil; it doesn't hit us directly, or indirectly it does; but the real challenge is in Europe, though we're seeing much better seasonal conditions in Southern Europe this year compared with last year; and as I said, given the very wet conditions in the U.K. and Northern Europe, we're now really seeing that shift occur from Q2 into Q3; and I'd expect that inventory to work its way through over the course of 2024.
John Purtell
analystAnd regarding Europe, clearly it fell a lot during the last half, and you've mentioned a few of those timing and weather problems there. But what about some of the other elements in play? Clearly, there have been some under-recoveries, which you've kind of flagged, but you also should have gotten some gain from reduced regulatory outs?
Gregory Hunt
executiveWell, yes. But once more, I believe that has really been offset somewhat by the seasonal conditions in the first half. I think another thing I'd highlight in Europe is Wyke, so the industrial sales is we produce products at that plant that we sell to third parties, basically our competitors and into the green roofs market in China; and once more, because of destocking, demand from those industrial customers has been weaker and demand for the inhibitors business into China has been lower because of the downturn in the property market; now I would expect that to persist from a wide perspective through the second half of '24. But Wyke has been a major component of the underperformance in Europe in the first half versus last year.
John Purtell
analystAnd one last thing, a question for Paul. Regarding the working capital unwind in the second half. I believe your uplift in the first half came to roughly $300 million, so you're basically assuming a larger unwind than that in the second half, Paul. And is receivables what drives that? I suppose historically, generally, if that first half build unwinds in the second half, that's typically the base case, but you're factoring in something beyond that?
Paul Townsend
executiveYes, so we used that illustration, John. I mean, we can only plan based on what happens historically, et cetera. So that's why we called out that on average, $533 million reduction; but it's fair to say we're also expecting, if you like, a narrowing between the inventory and payables position. So a little bit should come through there as well. But the lion's share, call it, $500 million plus, is going to come from the receivables unwind, and then you'll get a bit through the inventory reduction and payables squeezing.
William Park
analystThank you, Greg and Paul, for the presentation and for your time. Regarding that $26.7 million idle plant capacity charge sitting in your account, could you walk us through what you expect for the second half, if there's any?
Paul Townsend
executiveWe do anticipate that some idle plant capacity will carry on, so to speak, below the line. Most of it will be Wyke, and that reflects the significant disruptions we're experiencing not only with the existing investments we're making but also with this major CapEx upgrade. Because of those interruptions, we essentially, so to speak, normalize overhead recovery, which gives us a truer, so to speak, normalized position for the operation. So yes, expect some additional charges below the line in the second half.
William Park
analystCould you walk us through what that might look like in the second half, or?
Paul Townsend
executiveIt won't be as large as the first half. I'll simply say we aren't guiding on that at this point, purely because we're planning for a number, though that could change given the variability in the work schedule.
William Park
analystTurning to your full-year EBITDA guidance, I appreciate the midpoint for second-half EBITDA coming in at 25% year on year. Could you walk us through what growth we ought to consider regarding seed technologies and crop protection? Should we expect that 20-plus-percent growth we've observed in seed technologies to carry on into the second half? Or does it speed up while Crop Protection serves as the balance? Is that the way you're viewing it? Or are there additional moving parts we should keep in mind?
Paul Townsend
executiveOkay. Greg addressed Crop Protection quite thoroughly, I think. Another factor on seed is that in last year's second half we're lapping a large figure for licensing revenues. That places some downward pressure on seed results. So we anticipate seeds will come in slightly under last year, driven mainly by this phasing of licensing income and, in addition, seed treatment. Seed treatment will therefore be lower because of the destocking Greg mentioned in the speech; we also have somewhat greater investment in SG&A to support the business's growth. Then there's the year-on-year lap of this decline in licensing income. Broadly speaking, we called out $37 million for BP last year; this year it will be $20 million; that's a $17 million decline; that is the bridge.
James Ferrier
analystYou presented a few charts today about price deflation in Crop Protection chemicals. Which do you think hits your earnings harder as a headwind: the actual size of the premium or discount versus the main historical pricing? Should that be our focus? Or does the sequential path of pricing matter more? I'd just like some color on that, please.
Paul Townsend
executiveSo James, does your question relate to the FY '26 aspirations?
James Ferrier
analystNo, the real question is more — I'm on Slide 18, looking at that chart, and it's clear pricing has swung quite a bit over time, which is no surprise. But what I'm really trying to get at is this: is it the highs and lows in absolute terms compared with historical averages that mainly drive your business? Or does it come down to the sequential change and the fact that, say, it's beginning to edge upward now, which gives an immediate, direct boost to earnings? Or do we have to wait for that gap to close fully before you'd say there's a favorable earnings inflow?
Paul Townsend
executiveIt's sequential. When that shifts, we should see a favorable move, since the market reflects current price; and when prices go up, you typically get margin expansion because you're holding cheaper inventory, and that's what we've observed. Previously, that's what occurred in FY '22, when we called it out — that's why margins expanded, with your pricing rising along the curve while inventory cost stayed lower; likewise here, as the price climbs, you should again see expanded margins.
Gregory Hunt
executiveAnd I think, James, we've been through quite a turbulent stretch, correct? The chart makes that clear. If you looked at the big rise from the midpoint of '21 to '22, we moved from 15% below the averages to 40% above, and then between mid-'22 and mid-'24, we went from 40% above to 25% below. And I suppose what we're really saying is that as supply and demand normalizes, we're seeing a trend, if you will, or a tailwind as we head toward 2026. I think back in '22, we said there was $300 million coming from price or industry growth. And we said there would be a net $500 million from NPIs. So if we take where we stand today, what we're saying is that if you carry that trend forward to 2026, for example, you could expect to see somewhere between $400 million and $600 million of revenue upside from price movements. We've said we're halfway through the NPI, so you could add another $200 million, $250 million of revenue from where we are today when it comes to NPIs.
James Ferrier
analystThat helps, Greg. My second question concerns the base seed business. You called the performance very strong; however, once you account for the greater licensing revenue in the first half relative to PCP, plus likely growth in omega-3 revenue and earnings again versus PCP, it appears base seed earnings fell year-on-year, though maybe I'm overlooking something.
Paul Townsend
executiveBase seed is up, James. What you're seeing is a decline in seed treatment. In addition, we put money into SG&A to support the growth performance, which is absolutely, in effect, part of the offsets, the base seeds business <<inaudible>>.
Owen Birrell
analystAnd just a quick follow-up, really, to what James asked about that chart on herbicide pricing. I'm just curious — since you're describing that sequential movement in price, what kind of price outlook is baked into your EBITDA guidance for the second half? Are you assuming it stays flat? Or are you assuming some percentage increase in pricing as you go through that second half?
Gregory Hunt
executiveOur assumption is relatively flat. The bulk of the improvement in the second half, as we said, comes from volume.
Jonathan Snape
analystPerhaps just to build on what James was asking about, and you may have addressed this with the '26 targets. I'm looking at AgChem and the rolling 12 months, where things stand now versus where they'll end up? I think you laid that out in numbers, but roughly a 30% revenue uplift is needed, and it seems nearly all of it has to come from price. So I guess I follow this trade data the way you folks do too. And looking at volumes out of China this year, 20% above where they were in that big run in '21, '22, which seemed really supply chain driven at the time. But prices remain materially below those levels. What I'm trying to figure out is this: if the quantities being shipped are significantly larger while prices are weaker, what is going to cause a sudden reversal? Since it appears that some portion of the cycle-average price reflects a stretch marked by substantial supply-side turbulence, clear skies, and similar factors — conditions that in all likelihood won't recur — perhaps prices won't get back to that level. So how crucial is that pricing lever for reaching most of the targets? And what will abruptly make it occur?
Paul Townsend
executiveFirst, on the bridge from FY '24 to FY '26 — roughly speaking, we're assuming a 20% price recovery, so about $600 million; and with the NPIs, we're looking at somewhere in the range of $200 million to $300 million. So that's, if you like, the bridge to how we reach the aspirations, but around 20% is what we're expecting. By expecting, I mean that's what we calculated as, if you like, a reversion to average pricing — long-term average pricing, sorry.
Richard Johnson
analystMaybe I could pick up where Snape left off on the long-term target, and obviously those numbers are on the table there, but just thinking conceptually, when you assembled that target, presumably you didn't originally take into account the price declines seen in recent times. So let me ask the same thing a different way. What is going to compensate for that middle stretch of underperformance on the road toward the target at the latter end? I'm just trying to figure out where you recover what's been lost over the last couple of years.
Paul Townsend
executiveSo take a look at that chart. Back when we released the FY '22 aspirations in February '22, we actually relied on '21 prices. Our starting point is '21 pricing paired with our '21 actuals, and that's the bridge we're working from. So as you can see, they're going back toward a long-term average that sits a little lower, which means there's arguably some upside in pricing versus the '21 average prices we achieved, if you will. We did examine that specifically to set long-term average prices against the FY '21 base we walked from, and pricing came in somewhat under the longer-term average. So I suppose that's one data point we actually looked at to ask: alright, is it then sensible to project those average prices forward onto the planned volumes? And that's how we get to the bridge I just walked Snape through, with the 20% price and $200 million to $300 million in NPIs. And with that $200 million to $300 million in NPIs, if you return to those aspirations, we're fairly well at the halfway mark, and we've had $600 million of the NPIs net of cannibalization, et cetera. So it ends up being a bit of a thing from a maths standpoint.
Scott Ryall
analystI believe it's on that same flavor, and I was also taking a look at pricing. If you could just comment on Slide 19, you noted that the bulk of the crop protection market today is off patent, which gives you a chance to come in with some of your solutions. But given that we're off patent, why doesn't this look more like a commodity industry, where excess supply from China has permanently shifted the market clearing price, as you've seen happen with a lot of other commodities, high-profile ones, over the last couple of years? I'm just curious whether you could address that, please.
Gregory Hunt
executiveWell, I think the premise in what you said was excess supply coming out of China. I mean, I have no evidence of materially increased installed capacity being added in China during the period we're discussing; so if you look at them, as I mentioned, from midpoint '21 to midpoint '22, that was really all COVID driven, in that we couldn't get supply out of China. So we saw the pull forward, and then we saw China open up and products began to flow. What's happened, and part of the reason I think we moved back, is that the inventory we've seen on farm and in the channel during that period is now being sold through; so as you begin to restock and replenish, demand increases, capacity in China is still the same, prices should move up. That's my hypothesis.
Gregory Hunt
executiveThank you, Ashley, and thanks to all of you for being on today's call. I'm aware that we have a number of meetings scheduled with many of you over the coming week or so. So I'm looking forward to those discussions. Thanks, Ashley, and thanks to all of you for joining.
Operator
operatorThat brings us to the end of today's conference. We appreciate your participation. You can disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nufarm Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nufarm Limited earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nufarm Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.